Doxepin: a useful adjunct in the treatment of heroin addicts in a methadone program.
An uncontrolled trial of doxepin as an adjunct to treatment of heroin addicts in a methadone program was performed over a 14-month period. Approximately 10% (27) of the program's population utilized a mean of 73 mg of doxepin, usually briefly, and beneficial results were noted in 93% (25). One adverse reaction occurred. No instance of habituation or addiction was noted. A controlled study is warranted to confirm the impression that doxepin represents a useful adjunct in the treatment of heroin addicts in a methadone program.
D000328:Adult; D000368:Aged; D001007:Anxiety / Q000188:drug therapy; D002140:California; D004316:Doxepin / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006556:Heroin Dependence / Q000534:rehabilitation*; D006801:Humans; D008297:Male; D008691:Methadone / Q000627:therapeutic use*; D008875:Middle Aged; D013997:Time Factors
D004316:Doxepin; D008691:Methadone